A big pharmaceutical company (market value over $1 billion) will announce a deal to buy, partner with, or license a ketamine clinic operator—outfits like Field Trip or Ketamine Wellness Centers. Ketamine is already legal (Schedule III, less restricted), generates real clinic revenue, and poses no Schedule I legal risk, so pharma companies view clinic infrastructure as a safer way to enter the psychedelic space without the regulatory chaos of Schedule I compounds. This could happen by September 2026.
Ketamine is already Schedule III, generating clinic revenue, and legally de-risked relative to Schedule I psychedelics. The clinic infrastructure buildout (Field Trip, Ketamine Wellness Centers, etc.) represents an acqui-hire opportunity for pharma seeking psychedelic-adjacent positioning without Schedule I legal exposure. Johnson & Johnson's Spravato franchise demonstrates commercial viability. The >$1B market cap qualifier ensures this is a meaningful corporate actor, not a shell deal. Q3 2026 deadline is specific and near-term.